Previous studies indicate that even though afatinib is a more potent inhibitor of EGFR than osimertinib (for WT EGFR, IC50 of 0.5 nM for afatinib30 compared to 493.8 nM for osimertinib31), osimertinib had an advantage in clinical trials of non‐small cell lung cancer (NSCLC) with brain or central nervous system (CNS) metastases.32, 33. The gene discussed is EGFR; the disease is lung cancer.